Compare ALCO & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALCO | IPHA |
|---|---|---|
| Founded | 1960 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.9M | 189.5M |
| IPO Year | 1994 | N/A |
| Metric | ALCO | IPHA |
|---|---|---|
| Price | $41.26 | $1.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $44.00 | $5.75 |
| AVG Volume (30 Days) | ★ 19.4K | 8.8K |
| Earning Date | 05-11-2026 | 03-26-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.32 | $1.18 |
| 52 Week High | $45.01 | $2.63 |
| Indicator | ALCO | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 51.21 |
| Support Level | $39.94 | $1.73 |
| Resistance Level | $42.06 | $1.80 |
| Average True Range (ATR) | 0.82 | 0.09 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 84.51 | 27.60 |
Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.